WTF Happened to Bind Therapeutics?

It's hard to say just how many publicly traded stocks we've covered so far on Nanalyze, but we'd guess that around 40% of our articles involve a publicly traded stock that has some degree of exposure (or claimed exposure) to one or more emerging technologies. If we take out all the over the counter (OTC) garbage, we've probably covered somewhere around 180 publicly traded companies from across the globe. Of these, we've made investments in but a small handful. The truth is that technology investing is extremely risky, even in a bull market. Take Bind Therapeutics (OTCMKTS:BINDQ) as an example. We first wrote about Bind back in August of 2014 with an article titled "Nano Drug Delivery IPO of Bind Therapeutics". We liked the story they were telling (never invest in a story), and decided to pick up a small block of shares. Here is how well that position has performed: Now we have to fill out some dumb form and then we may get a few dollars in the future after bankruptcy proceedings are
Subscribe or log in to access our premium content including 250+ premium articles, insightful analytic reports on AI investments for retail investors, and our magnum opus: "Quantigence – A Dividend Growth Investing Strategy".

Leave a Reply

Your email address will not be published. Required fields are marked *

There’s Plenty of Room at the Bottom

And plenty of insights in our awesome newsletter.

4 Shares
Tweet2
Share2
Share
Reddit
Buffer